






Why NattoPine Clobbers the Competition
How does your blood clot and circulation supplement compare?

Based on recommended daily usage.					
	NATTOPINE	NOW NATTOKINASE	SOURCE NATURALS NATTOKINASE	JARROW'S NATTOMAX	ARG NATTOKINASE
Nattokinase*	3650 FU**	2000 FU	2000 FU	2000 FU	2000 FU
Pine bark extract†	300 mg				
Deep Vein Thrombosis Prevention in Humans‡	100%	Never studied	Never studied	Never studied	Never studied
Leg Swelling (edema) Decrease‡	27%	Never studied	Never studied	Never studied	Never studied
					

****Nattokinase** is an extract from a Natto, a Japanese food from fermented soybeans. Nattokinase promotes healthy blood clotting by preventing and breaking up clots. **NattoPine contains the highest dose of nattokinase of any product.** NattoPine also contains powerful antioxidants from pine bark extract to protect blood vessels from damaging free radicals.

NattoPine's ingredients were shown in a clinical trial to reduce the risk of deep vein thrombosis by and leg swelling. In the clinical trial nearly 10% of people not taking the nattokinase and pine bark extract combination experienced a deep vein thrombosis versus none of those taking the dietary supplement. In other words, blood clots were prevented in 100% of people taking NattoPine's formula. Those taking nattokinase and pine bark extract also had a 27% decrease in risk of leg swelling (edema).

****FU** (fibrinolytic units). FU is how manufacturers measure the blood dissolving strength of nattokinase. The high the FU, the stronger and more effective the product.

†**Pine bark extract** is a powerful antioxidant shown to promote healthy circulation. The combination and strength of pine bark extra and nattokinase in NattoPine is the only formula studied in a human clinical trial.

‡Results based on a published human clinical trial (*Angiology*.2003;54(5):531-539).

References: Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial, by Cesarone MR et al. *Angiology*. 2003;54(5):531-539. **Natto diet was apparently effective in a case of incipient central retinal vein occlusion**, by Nishimura, K. et al. *Japan Rev Clin Ophthalmol* 1994, 88:1381-85. **Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase**, by Sumi, H. et al. *Acta haematol* 1990, 84: 139-43.

DISCLAIMER: These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.